Impact of Pulmonary Comorbidities on COVID-19: Acute and Long-Term Evaluations
Journal of Clinical Medicine · 21.02.2025 · 14 (5) · 1446
DOI: 10.3390/jcm14051446 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.02.2025. Verfasst von Gabriela Mara und 2 weiteren Autor:innen. Beteiligte Einrichtung: Multidisciplinary Doctoral School, Vasile Goldis Western University of Arad, 310414 Arad, Romania. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Pulmonary comorbidities, such as chronic obstructive pulmonary disease (COPD), asthma, and interstitial lung diseases (ILDs), have emerged as critical factors influencing the severity and outcomes of COVID-19. This review aims to evaluate the interplay between these comorbidities and COVID-19, both during the acute phase and in long-term recovery, focusing on their impact on clinical management and outcomes.
Methods
This systematic review examined studies sourced from major medical databases, including PubMed and Scopus, using keywords such as “COVID-19”, “pulmonary comorbidities”, “long COVID”, and “respiratory sequelae”. Peer-reviewed articles published from January 2020 to the present were included, with data extracted to evaluate both the acute and long-term effects of these comorbidities on COVID-19 patients.
Results
Patients with COPD demonstrated significantly higher risks of severe COVID-19, including increased hospitalization and mortality. Asthma, while less consistently associated with severe outcomes, showed a variable risk based on disease control. ILDs were strongly correlated with poor outcomes, including higher rates of respiratory failure and mortality. Long-term complications, such as persistent dyspnea, impaired lung function, and structural changes like fibrosis, were prevalent in patients recovering from moderate to severe COVID-19. These complications adversely affected quality of life and increased healthcare dependency.
Conclusions
Pulmonary comorbidities amplify both the acute severity and long-term respiratory consequences of COVID-19. Effective management necessitates tailored strategies addressing both phases, integrating rehabilitation and continuous monitoring to mitigate chronic impairments. Future research should prioritize understanding the mechanisms behind these interactions to inform public health interventions and improve patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Multidisciplinary Doctoral School, Vasile Goldis Western University of Arad, 310414 Arad, Romania.
- Pneumology Department, Vasile Goldis Western University of Arad, 310414 Arad, Romania.
- Clinical Hematology Department, Vasile Goldis Western University of Arad, 310025 Arad, Romania.
Zitieren
APA
Mara, G., Nini, G., & Cotoraci, C. (2025). Impact of Pulmonary Comorbidities on COVID-19: Acute and Long-Term Evaluations. Journal of Clinical Medicine, 14(5), 1446. https://doi.org/10.3390/jcm14051446
Vancouver
Mara G, Nini G, Cotoraci C. Impact of Pulmonary Comorbidities on COVID-19: Acute and Long-Term Evaluations. Journal of Clinical Medicine. 2025;14(5):1446. doi:10.3390/jcm14051446
BibTeX
@article{Mara2025,
author = {Mara, Gabriela and Nini, Gheorghe and Cotoraci, Coralia},
title = {Impact of Pulmonary Comorbidities on COVID-19: Acute and Long-Term Evaluations},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {5},
pages = {1446},
doi = {10.3390/jcm14051446}
}
EUVIMED